Your browser is no longer supported. Please, upgrade your browser.
Settings
GSK GlaxoSmithKline plc daily Stock Chart
GSK [NYSE]
GlaxoSmithKline plc
Index- P/E8.67 EPS (ttm)5.00 Insider Own0.20% Shs Outstand2.44B Perf Week0.49%
Market Cap105.65B Forward P/E16.76 EPS next Y2.59 Insider Trans0.00% Shs Float2.43B Perf Month6.54%
Income12.06B PEG14.45 EPS next Q0.29 Inst Own9.10% Short Float0.16% Perf Quarter10.10%
Sales34.26B P/S3.08 EPS this Y204.10% Inst Trans0.33% Short Ratio1.05 Perf Half Y8.70%
Book/sh3.03 P/B14.31 EPS next Y3.69% ROA15.40% Target Price47.33 Perf Year-0.44%
Cash/sh3.47 P/C12.49 EPS next 5Y0.60% ROE135.80% 52W Range35.58 - 43.94 Perf YTD10.89%
Dividend2.62 P/FCF- EPS past 5Y40.20% ROI41.40% 52W High-1.33% Beta0.80
Dividend %6.04% Quick Ratio0.90 Sales past 5Y-3.40% Gross Margin66.40% 52W Low21.86% ATR0.53
Employees101192 Current Ratio1.20 Sales Q/Q1.60% Oper. Margin46.70% RSI (14)67.72 Volatility0.87% 1.07%
OptionableYes Debt/Eq3.25 EPS Q/Q-134.10% Profit Margin35.20% Rel Volume0.90 Prev Close43.47
ShortableYes LT Debt/Eq3.00 EarningsApr 27 Payout45.80% Avg Volume3.75M Price43.36
Recom2.00 SMA202.78% SMA506.64% SMA2009.45% Volume3,400,000 Change-0.25%
Mar-30-16Upgrade Citigroup Neutral → Buy
Feb-26-16Initiated Cantor Fitzgerald Hold
Dec-09-15Upgrade BofA/Merrill Neutral → Buy
Dec-07-15Reiterated Argus Buy $52 → $48
Oct-20-15Upgrade Credit Suisse Underperform → Neutral
Sep-15-15Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-15Upgrade BofA/Merrill Underperform → Neutral
Jun-26-15Upgrade Liberum Sell → Hold
Jun-04-15Downgrade Morgan Stanley Overweight → Equal-Weight
May-20-15Resumed Citigroup Neutral
Apr-15-15Initiated Societe Generale Sell
Feb-19-15Reiterated Argus Buy $55 → $52
Aug-08-14Reiterated Argus Buy $65 → $55
Apr-23-14Upgrade Argus Hold → Buy
May-28-13Upgrade Deutsche Bank Hold → Buy
Jan-11-11Upgrade Jefferies Hold → Buy
Jun-02-10Upgrade Jefferies Hold → Buy
Feb-16-10Upgrade JP Morgan Underweight → Neutral $26
Jan-13-10Downgrade Credit Suisse Outperform → Underperform
Nov-24-09Initiated Leerink Swann Mkt Perform
Apr-29-16 05:24AM  Glaxo's Mouthwash-Inspired Gel for Babies Wins EU Agency Backing at Bloomberg
Apr-28-16 03:12PM  How Did Eli Lilly Perform in 1Q16? Market Realist
01:06PM  GlaxoSmithKline (GSK) Q1 Earnings Lag, Revenues Up Y/Y Zacks
Apr-27-16 05:17PM  Advocates hold NYC protest over price of pneumonia vaccine AP
02:40PM  Glaxo Finally Finds Some Momentum at Bloomberg
11:55AM  GlaxoSmithKline Shares Boosted by Strong First-Quarter Update at TheStreet
10:48AM  [$$] GlaxoSmithKline Posts Healthy Profit With Earnings Rise at The Wall Street Journal
09:56AM  GSK finds axing doctor payments needn't torpedo sales Reuters
09:21AM  GSK sees rise in sales of vaccines, healthcare products AP
09:11AM  Glaxo CEO: Price Pressure Continues in United States Bloomberg
08:41AM  Glaxo (GSK) Misses on Q1 Earnings, Revenues Rise Y/Y Zacks
07:30AM  [$$] Zymeworks Forms Second Collaboration With GlaxoSmithKline at The Wall Street Journal
07:23AM  New products and vaccines a shot in the arm for GSK at CNBC
07:10AM  Better margins and new drugs keep GlaxoSmithKline on track Reuters
07:05AM  Glaxo Profit Rises for First Time Since 2013, Tops Estimates at Bloomberg
Apr-26-16 07:05PM  Other Drugs under Development at Ionis Pharmaceuticals Market Realist
06:46PM  [$$] Welcome initiatives in affordable therapies at Financial Times
07:27AM  [$$] Allied Minds Supports Bristol-Myers Partnership With $80M Fund at The Wall Street Journal
Apr-25-16 11:34AM  Novartiss 1Q16 Earnings Got a Neutral Response from Investors Market Realist
11:34AM  Novartis Reported Operational Growth in Its 1Q16 Earnings Market Realist
07:08AM  Big Drug Stocks to Report This Week: LLY, GSK, VRTX, BMY, ABBV Zacks
Apr-24-16 07:16PM  [$$] Vaccine development needs global alliance at Financial Times
07:13PM  [$$] Vaccines are among big pharma's best-selling products at Financial Times
Apr-22-16 06:50PM  Study: No suicide risk for anti-smoking pills Chantix, Zyban AP
12:08PM  Glaxo (GSK) Q1 Earnings: What's in Store for the Stock? Zacks
12:30AM  [$$] Glaxo Investors Want CEO Who Can Revitalize R&D at The Wall Street Journal
Apr-21-16 09:00AM  How These Drug Manufacturers BMY, LLY, AZN, and GSK are Performing Accesswire
05:30AM  [$$] Glaxo Investors Want CEO Who Can Revitalize R&D at The Wall Street Journal
Apr-20-16 09:53AM  Searching for Volatility and Value in a Low Vol Market Bloomberg
09:05AM  GlaxoSmithKline & California research institute create center to study brain disorders at American City Business Journals
12:00AM  Glaxo May Need to Boost Pay to Lure U.S. CEO Candidates at Bloomberg
Apr-19-16 03:41PM  Jim Cramer -- Johnson & Johnson Is a Standout Among Drug Stocks at TheStreet
12:03PM  Jim Cramer -- Skip GlaxoSmithKline, but Buy Johnson & Johnson at TheStreet
Apr-16-16 02:18PM  The Race to Cure the Zika Virus is On, and This Company May Have the Best Solution at Motley Fool
Apr-15-16 09:07AM  Understanding Ionis Pharmaceuticals 2015 Revenue Stream
Apr-13-16 02:40PM  Glaxo, IP and PetMed Poised to Go Higher at TheStreet
Apr-12-16 08:10AM  3 Nominations for Big Pharma's Riskiest Pipeline -- and Why They Qualify at Motley Fool
01:05AM  How Is Novo Nordisk Doing in the Diabetes Space?
Apr-11-16 10:07AM  Consumer Healthcare Should Be a Key Driver of Perrigos 2016 Growth
Apr-09-16 03:24PM  Here's Why Dynavax Technologies Corporation's Stock Gained 14.5% In March at Motley Fool
06:42AM  The Biggest Threat to Novavax Stock at Motley Fool
Apr-08-16 05:26PM  Market Dynamics Should Strengthen Perrigos OTC Business in 2016
04:40PM  Ionis Tanks, FDA Clinical Hold on IONIS-TTRRx Phase III Study
10:05AM  How Risky Is Dynavax Technologies Stock? at Motley Fool
08:15AM  3 Healthcare Funds to Buy on Biotech Rebound
Apr-07-16 01:19PM  Why Ionis Pharmaceuticals Inc Couldn't Hold Its Price Today at Motley Fool
12:10PM  Ionis Stumbles on FDA Clinical Hold
11:39AM  Here's Why Ionis Pharma (IONS) Stock is Sinking Today at TheStreet
Apr-06-16 05:28PM  Why Johnson & Johnson Is Ramping Up Its Business in Africa at Fortune
04:06PM  Tevas Asthma Segment: What Could Its Boost Revenues in 2016?
04:04PM  What Are Novartiss Valuation Multiples?
11:00AM  Tax Clampdown Prompts Pfizer to Scrap Allergan Purchase
06:14AM  European Stocks Stabilize as Health Care Gains at TheStreet
Apr-05-16 07:28AM  Pfizer Vs. Obama: The Treasury Tries To Stop Pharma's Tax Dodge at Forbes
Apr-04-16 05:29PM  Glaxo's (GSK) Strimvelis Gets CHMP Nod for Rare Disorder
01:04PM  Better Buy: Eli Lilly and Co. vs. GlaxoSmithKline at Motley Fool
12:09PM  GlaxoSmithKline Is One Step Closer to EU Approval for Its Gene Therapy at Fortune
Apr-02-16 10:48PM  FPHAX: Fidelity Select Pharma Fund Top 5 Holdings Analysis at Investopedia
Apr-01-16 04:08PM  Market Response to EMA Validation of Opdivo Application
04:08PM  Checkmate-205: Studies Supporting Opdivos Application
12:20PM  Glaxo's Potential Cure for 'Bubble Boy Disease' One Step Closer at The Wall Street Journal
11:07AM  Exploring Pfizers Recent Corporate Developments
10:34AM  Europe gives green light to first gene therapy for children Reuters
10:27AM  Glaxo's `Bubble Boy' Gene Therapy Wins EU Drug Agency Nod at Bloomberg
07:01AM  Glaxo Marvelously Upends TPP And TTIP With Change In IP Policies For Poor Countries at Forbes
Mar-31-16 05:26PM  Opdivo: Bristol-Myers Squibbs Blockbuster Drug
02:35PM  Big Pharma companies that have paid the most in fines at bizjournals.com
12:58PM  Glaxo to Stop Seeking Drug Patents in Low-Income Countries at The Wall Street Journal
12:08PM  Introducing Krystexxa, the Latest Addition to Horizons Orphan Portfolio
10:47AM  GlaxoSmithKline Is Expanding Drug Access to the Worlds Poorest Countries at Fortune
10:28AM  GSK announces plans to make drugs more affordable in poor countries at bizjournals.com
Mar-30-16 12:07PM  Heres How GlaxoSmithKlines CEO Thinks Pharma Should Modernize at Fortune
10:43AM  Inovios Ebola vaccine has positive results in early human trials at MarketWatch
08:04AM  GlaxoSmithKline Reaffirms Its Commitment To Oncology Research But The Strategy Is Unclear at Forbes
07:15AM  GlaxoSmithKline upgraded by Citigroup
Mar-29-16 02:30PM  3 High-Risk Dividend Stocks to Avoid at Motley Fool
02:33AM  GSK receives marketing authorisation for Nucala® (mepolizumab) in Japan at noodls
01:07AM  What Do Analysts Estimate for Novartis?
Mar-25-16 03:41PM  Which of These Two High-Dividend Yielding Stocks Can Investors Buy? at Motley Fool
Mar-24-16 04:43PM  With Andrew Witty's Departure, Will GlaxoSmithKline Say Goodbye to Fraud? at Forbes
03:04PM  Will Novartiss 1Q16 Revenues Fall as Expected?
02:59PM  What to Expect from Novartiss 1Q16 Earnings
01:04PM  GLAXOSMITHKLINE PLC Financials
Mar-23-16 05:37PM  Why the UK Is Headed for a Slowdown
Mar-22-16 09:10AM  Which Big Pharma Is the Best Dividend Stock? at Motley Fool
08:03AM  What GSK CEO Andrew Witty Doesn't Get About Drug Pricing at Forbes
Mar-21-16 04:45PM  Dollars spent advertising GSK drug made in Zebulon among industry's highest at bizjournals.com
04:04PM  GlaxoSmithKline's Search for a New CEO May Revive Underlying Uncertainties at Motley Fool
01:01PM  Better Buy: GlaxoSmithKline plc vs. Johnson & Johnson at Motley Fool
12:31PM  What Should We Think About the Passive Offering of VEURX?
Mar-19-16 10:05AM  4 High-Yield Dividend Stocks to Buy in March at Motley Fool
Mar-18-16 06:00PM  Insiders Roundup: Theravance Biopharma, Western Gas, Upland Software
03:09PM  [$$] Week in Review, March 18 at Financial Times
11:23AM  A New Look At Some Of The Most Innovative Pharma Companies (And Whether They Are Sustainable) -- Part I at Forbes
08:10AM  Eli Lilly's Product Pipeline and Growth Prospects Make It a Strong Buy at TheStreet
Mar-17-16 11:15PM  GlaxoSmithKline Says Andrew Witty to Retire as CEO at The Wall Street Journal
04:30PM  [$$] Glaxo CEO Andrew Witty to Retire at The Wall Street Journal
04:11PM  One Reason Why GlaxoSmithKline (GSK) Stock Closed Up Today at TheStreet
02:31PM  Witty's Glaxo Long on Ideas, Short on Return at Bloomberg
01:42PM  [$$] Sir Andrew Witty's tenure at GSK divides opinion at Financial Times
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The company's wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The company's nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc has collaboration agreements with Universit de Sherbrooke and Pfizer Inc.; development agreement, and R and D collaboration with Propeller Health; R and D collaboration agreement with Valneva SE; and collaboration and license agreement with Idera pharmaceuticals, Inc. The company was founded in 1935 and is headquartered in Brentford, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLC10% OwnerMay 11Buy14.00365,1065,111,484365,106May 13 12:36 PM